Francois Brisbois's questions to Simulations Plus Inc (SLP) leadership • Q2 2025
Question
An analyst on behalf of Francois Brisbois at Oppenheimer & Co. Inc. asked for color on the 89% growth in the QSP business unit, specifically the customer profile for the atopic dermatitis model. He also inquired about the growth outlook for QSP and other potential indications the company is targeting.
Answer
Executive Shawn O'Connor explained that the strong QSP growth was driven by a large, high-ticket model license (upwards of $500k), which makes quarterly results lumpy. These licenses are typically sold to large pharma clients. He advised against projecting the 89% growth rate forward, suggesting instead to look at QSP growth on an annual basis. While he did not name specific new indications, he noted that QSP disease model licensing is a strong growth area, with smaller licenses providing more consistent quarterly revenue.